Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland.
Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Laboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.
Biotechnol Adv. 2019 Nov 1;37(6):107369. doi: 10.1016/j.biotechadv.2019.03.008. Epub 2019 Mar 12.
Over the last decade, there has been an increasing scientific and public interest in bacteria that may positively contribute to human gut health and well-being. This interest is reflected by the ever-increasing number of developed functional food products containing health-promoting bacteria and reaching the market place as well as by the growing revenue and profits of notably bacterial supplements worldwide. Traditionally, the origin of probiotic-marketed bacteria was limited to a rather small number of bacterial species that mostly belong to lactic acid bacteria and bifidobacteria. Intensifying research efforts on the human gut microbiome offered novel insights into the role of human gut microbiota in health and disease, while also providing a deep and increasingly comprehensive understanding of the bacterial communities present in this complex ecosystem and their interactions with the gut-liver-brain axis. This resulted in rational and systematic approaches to select novel health-promoting bacteria or to engineer existing bacteria with enhanced probiotic properties. In parallel, the field of gut microbiomics developed into a fertile framework for the identification, isolation and characterization of a phylogenetically diverse array of health-promoting bacterial species, also called next-generation therapeutic bacteria. The present review will address these developments with specific attention for the selection and improvement of a selected number of health-promoting bacterial species and strains that are extensively studied or hold promise for future food or pharma product development.
在过去的十年中,人们对可能对人类肠道健康和福祉产生积极影响的细菌越来越感兴趣,无论是科学界还是公众都是如此。这方面的兴趣反映在不断增加的含有促进健康的细菌的功能性食品产品的数量上,这些产品已经投放市场,同时也反映在全球范围内细菌补充剂的收入和利润不断增长。传统上,商业化益生菌的来源仅限于少数几种细菌,这些细菌主要属于乳酸菌和双歧杆菌。对人类肠道微生物组的研究不断深入,为人们了解肠道微生物群在健康和疾病中的作用提供了新的见解,同时也深入了解了存在于这个复杂生态系统中的细菌群落及其与肠道-肝脏-大脑轴的相互作用。这为选择新型促进健康的细菌或对具有增强益生菌特性的现有细菌进行工程改造提供了合理和系统的方法。与此同时,肠道微生物组学领域发展成为一个识别、分离和表征具有进化多样性的促进健康的细菌物种的肥沃框架,这些细菌也被称为下一代治疗性细菌。本综述将特别关注选择和改进一些经过广泛研究或有希望用于未来食品或制药产品开发的具有促进健康作用的细菌种类和菌株的发展情况。